Skip to main navigation Skip to search Skip to main content

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Translated title of the contribution: Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
  • J.P. Clancy
  • , P. Campbell
  • , I. Bronsveld
  • , M. W. Konstan
  • , et al et al

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contributionResults of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Original languageUndefined/Unknown
Pages (from-to)12-18
Number of pages7
JournalThorax
Volume67
Issue number1
Publication statusPublished - 2012

Access to Document

Cite this